Post-earnings recap
Reported
Wed, May 8, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Apellis Pharmaceuticals is still in a challenging financial position, particularly with a significant loss per share. The stock reacted negatively, dropping 2.79%, likely due to the lack of revenue figures and guidance. Investors may be cautious as the company continues to navigate its clinical programs without clear financial direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.87 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their clinical programs. They acknowledged the challenges faced in the quarter but did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the current financial results.